^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    mezigdomide (CC-92480)

    i
    Other names: CC-92480, BMS-986348, A/I CELMoD, CC 92480, BMS986348, BMS 986348, CC92480
    Company:
    BMS
    Drug class:
    Cereblon modulator
    Related drugs:
    1d
    A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=4, Terminated, Celgene | N=156 --> 4 | Active, not recruiting --> Terminated; Business objectives have changed
    Enrollment change • Trial termination
    |
    dexamethasone • alnuctamab (CC-93269) • mezigdomide (CC-92480)
    9d
    MAGENTA: Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=25, Recruiting, Massachusetts General Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    dexamethasone • Talvey (talquetamab-tgvs) • mezigdomide (CC-92480)
    10d
    24CH294: A multicenter phase 2 study of Belantamab mafodotin and Mezigdomide in combination with a phase Ib Safety run in patients with relapsed multiple myeloma following BCMA-targeting CAR-T cells or bispecific antibodies - The IFM 2024-01 clinical trial (BELAMI) (2025-520976-25-00)
    P1/2, N=44, Not yet recruiting, Centre Hospitalier Universitaire De Saint Etienne
    New P1/2 trial
    |
    Blenrep (belantamab mafodotin-blmf) • mezigdomide (CC-92480)
    14d
    A Phase 2, single arm Multicenter, Study testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM) (2025-521090-14-00)
    P1/2, N=70, Not yet recruiting, Assistance Publique Hopitaux De Paris
    New P1/2 trial
    |
    carfilzomib • dexamethasone • mezigdomide (CC-92480)
    15d
    Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma (clinicaltrials.gov)
    P1, N=15, Recruiting, City of Hope Medical Center | Trial completion date: Mar 2026 --> Sep 2026 | Trial primary completion date: Mar 2026 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    dexamethasone • Abecma (idecabtagene vicleucel) • mezigdomide (CC-92480)
    1m
    A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) (clinicaltrials.gov)
    P3, N=525, Active, not recruiting, Bristol-Myers Squibb | Trial primary completion date: Feb 2026 --> Jul 2026
    Trial primary completion date
    |
    carfilzomib • mezigdomide (CC-92480)
    2ms
    CA057-001: A trial to determine the safety and effectiveness of CC-92480 in combination with bortezomib and dexamethasone as compared to pomalidomide in combination with bortezomib and dexamethasone in people who have Multiple Myeloma that is not responsive after treatment or has returned after a period of treatment. (2023-509859-13-00`2021-001957-30)
    P2/3, N=322, Active, not recruiting, Celgene Corp. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    bortezomib • pomalidomide • mezigdomide (CC-92480) • dexamethasone injection
    2ms
    CA057-1040: Phase 1b/2a Study to Evaluate Mezigdomide in Combination with Elranatamab in Relapsed and/or Refractory Multiple Myeloma (2025-522090-11-00)
    P1/2, N=24, Recruiting, Celgene Corp.
    New P1/2 trial
    |
    dexamethasone • Elrexfio (elranatamab-bcmm) • mezigdomide (CC-92480)
    2ms
    A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) (clinicaltrials.gov)
    P3, N=525, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    carfilzomib • mezigdomide (CC-92480)
    2ms
    CC-92480-MM-001: A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (clinicaltrials.gov)
    P1/2, N=200, Terminated, Celgene | Trial completion date: Jan 2028 --> Oct 2025 | Active, not recruiting --> Terminated; Business objectives have changed
    Trial completion date • Trial termination
    |
    dexamethasone • mezigdomide (CC-92480)
    3ms
    Targeting Ikaros and Aiolos: Next-Generation Cereblon E3 Ligase Modulators in MM. (PubMed, Eur J Haematol)
    With frontline therapeutic strategies increasingly employing quadruplet induction regimens and prolonged lenalidomide maintenance, resistance to traditional IMiDs has become more prevalent, creating an urgent need for next-generation cereblon E3 ligase modulators (CELMoDs) capable of overcoming IMiD refractoriness and enhancing the immunologic microenvironment. Iberdomide (CC-220) and mezigdomide (CC-92480) are rationally engineered CELMoDs designed to achieve deeper degradation of Ikaros (IKZF1) and Aiolos (IKZF3), restore cereblon-mediated activity, and potentiate immune effector responses...We examine how their pharmacodynamic properties differ from classical IMiDs, their relevance in triple-class and penta-refractory MM, and their integration into emerging combination strategies with monoclonal antibodies and T-cell-redirecting immunotherapies. Special emphasis is placed on ongoing and future trials that may refine their therapeutic positioning, alongside a critical appraisal of the limitations and future directions of this rapidly advancing drug class.
    Review • Journal
    |
    IKZF1 (IKAROS Family Zinc Finger 1) • CRBN (Cereblon) • IKZF3 (IKAROS Family Zinc Finger 3)
    |
    lenalidomide • iberdomide (CC-220) • mezigdomide (CC-92480)
    3ms
    Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies (clinicaltrials.gov)
    P1, N=27, Recruiting, Abdullah Khan | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date • IO biomarker
    |
    IKZF1 (IKAROS Family Zinc Finger 1) • CRBN (Cereblon)
    |
    Empliciti (elotuzumab) • Hemady (dexamethasone tablets) • mezigdomide (CC-92480) • dexamethasone injection